UNITED THERAPEUTICS CORP (UTHR) Stock News

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

How Is The Market Feeling About United Therapeutics?

United Therapeutics Announces Successful World’s First UKidney Transplant

$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today

United Therapeutics Larger Than S&P 500 Component Baxter International

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

Electric Aircraft Startup Beta Raises $318 Million in New Round

Electric aerospace startup Beta Technologies Inc. raised $318 million from investors to fund the production of aircraft that can takeoff and land vertically.

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade

Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.

Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits

Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.

United Therapeutics Larger Than S&P 500 Component Kimco Realty

Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers

Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.

United Therapeutics Corporation to Present at Upcoming Investor Conferences

Biohaven Stock Earns Relative Strength Rating Upgrade

Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.

SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating

A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.

Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38%

The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI.